On Jan. 29, 2019, Ontario Institute for Cancer Research’s (OICR) Drug Discovery Program’s first-of-its-kind leukemia therapy discovery received approximately $1 billion in funding from Celgene Corporation, the largest transaction to date for a preclinical asset discovered in Canada.